In vitro Antioxidant, Acetylcholinesterase, and Amyloid-beta Inhibitory Effects of Captopril, An Angiotensin-Converting Enzyme (ACE) Inhibitor

Raghul Murugan; Vantipalli Raga Sai  Harshitha; Royapuram Parthasarathy  Parameswari; Anitha Roy

Authors

Raghul Murugan Department of Pharmacology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamil Nadu, India https://orcid.org/0000-0002-0864-4818
Vantipalli Raga Sai Harshitha Department of Pharmacology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamil Nadu, India
Royapuram Parthasarathy Parameswari Department of Biochemistry, Saveetha Medical College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Thandalam, Chennai, Tamil Nadu, India https://orcid.org/0000-0003-3167-2873
Anitha Roy Department of Pharmacology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamil Nadu, India https://orcid.org/0000-0002-8631-0936

Keywords:

health, diseases, antioxidant, neuroprotection, captopril, acetylcholinesterase, amyloid peptide

Abstract

Objective This study aims to investigate the potential of captopril, an angiotensin-converting enzyme (ACE) inhibitor, to reduce reactive oxygen species (ROS) production and address critical factors associated with Alzheimer’s disease (AD) pathology, including acetylcholinesterase (AChE) activity and amyloid-beta (A) peptide aggregation. The broader goal was to explore captopril’s neuroprotective properties and its potential as a therapeutic agent for AD.

Methods The antioxidant effects of captopril were evaluated using DPPH and ABTS assays, as well as xanthine oxidase inhibition tests. The impact of captopril on AChE activity and A $\ss$ aggregation was assessed through in-vitro experiments. Molecular docking studies were conducted to analyze captopril’s binding affinity with essential AD-related proteins.

Results Captopril demonstrated notable antioxidant activity with IC₅₀ values of 71.99±0.40 µM (DPPH) and 106.3±0.28 µM (ABTS), comparable to ascorbic acid (92.32 ± 0.26 µM and 110.1±0.24 µM). Significant inhibition of xanthine oxidase activity was observed; however, the IC₅₀ value exceeded the maximum tested concentration of 320 µM for both captopril and ascorbic acid. Captopril showed AChE inhibitory activity with an IC₅₀ of 208.2 ± 0.36 µM, whereas donepezil exhibited an IC₅₀ of 79.05 ± 0.25 µg/mL. In the A aggregation assay, captopril had an IC₅₀ of 87.69±0.25 µM, while donepezil also displayed significant inhibition, with an IC₅₀ above 320 µM. Molecular docking analyses revealed favourable binding interactions of captopril with AChE and A-related targets, supporting its multitarget mechanism.

Conclusions Captopril demonstrated notable neuroprotective effects, including antioxidant activity and the inhibition of AChE activity and A aggregation. These findings indicate that captopril holds promise as a therapeutic agent for AD, warranting further research and clinical trials to evaluate its efficacy in combating neurodegeneration.

References

Santiago TC, Parra L, Nani J V., Fidalgo TM, Bradshaw NJ, Hayashi MAF. Angiotensin‐converting enzymes as druggable features of psychiatric and neurodegenerative disorders. Angiotensin-converting enzymes as druggable features of psychiatric and neurodegenerative disorders. J Neurochem. 2023;166:138-55.

Yagi S, Akaike M, Ise T, Ueda Y, Iwase T, Sata M. Renin–angiotensin–aldosterone system has a pivotal role in cognitive impairment. Hypertens Res. 2013;36:753-8.

RP P, Ramesh G, Chidambaram SB, Thangavelu L. Oxi-dative stress mediated neuroinflammation induced by chronic sleep restriction as triggers for Alzheimer’s disease. Alzheimers Dement. 2022;18:e059016.

Cuddy LK, Prokopenko D, Cunningham EP, Brimberry R, Song P, Kirchner R, et al. A-accelerated neurodegeneration caused by Alzheimer’s-associated ACE variant R1279Q is rescued by angiotensin system inhibition in mice. Sci Transl Med. 2020;12:eaaz2541. PubMed PMID: 32998969

Kaur P, Muthuraman A, Kaur M. The implications of angiotensin-converting enzymes and their modulators in neurodegenerative disorders: current and future perspectives. ACS Chem Neurosci. 2015;6:508-21.

Fazal K, Perera G, Khondoker M, Howard R, Stewart R. Associations of centrally acting ACE inhibitors with cognitive decline and survival in Alzheimer’s disease. BJ Psych Open. 2017;3:158-64.

AbdAlla S, Langer A, Fu X, Quitterer U. ACE Inhibition with captopril retards the development of signs of neurodegeneration in an animal model of Alzheimer’s disease. Int J Mol Sci. 2013;14:16917-42.

Asraf K, Torika N, Apte RN, Fleisher-Berkovich S. Microglial activation is modulated by captopril: in vitro and in Vivo Studies. Front Cell Neurosci. 2018;12:116. PubMed PMID: 29765306

Aruoma OI, Akanmu D, Cecchini R, Halliwell B. Evaluation of the ability of the angiotensin-converting enzyme inhibitor captopril to scavenge reactive oxygen species. Chem Biol Interact. 1991;77:303–14.

Dong Y, Kataoka K, Tokutomi Y, Nako H, Nakamura T, Toyama K, et al. Perindopril, a centrally active angiotensin‐converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer’s disease. FASEB J. 2011;25:2911–20.

Murugan R, Rajesh R, Guru A, Haridevamuthu B, Almutairi BO, Almutairi MH, et al. Deacetylepoxyazadiradione Derived from Epoxyazadiradione of Neem ( Azadirachta indica A. Juss) Fruits Mitigates LPS‐Induced Oxidative Stress and Inflammation in Zebrafish Larvae. Chem Biodivers. 2022;19:e202200041. PubMed PMID: 36026548

González-Palma I, Escalona-Buendía HB, Ponce- Alquicira E, Téllez-Téllez M, Gupta VK, Díaz-Godínez G, et al. Evaluation of the antioxidant activity of aqueous and methanol extracts of pleurotus ostreatus in different growth stages. Front Microbiol. 2016;7:1099. PubMed PMID: 27462314

Nasim I, Shamly M, Jaju K, Vishnupriya V, Jabin Z. Antioxidant and anti-inflammatory activity of a nanoparticle based intracanal drugs. Bioinformation. 2022 May 31;18:450-4.

Guru A, Murugan R, Almutairi BO, Arokiyaraj S, Arockiaraj J. Brain targeted luteolin-graphene oxide nanoparticle abrogates polyethylene terephthalate induced altered neurological response in zebrafish. Mol Biol Rep. 2024;51:27. PubMed PMID: 38133875

Mugundhan V, Arthanari A, Parthasarathy PR. Protective effect of ferulic acid on acetylcholinesterase and amyloid beta peptide plaque formation in Alzheimer’s disease: an in vitro study. Cureus. 2024;16:e54103. PubMed PMID: 38487137

Andrew S. Molecular docking analysis of thiazo inhibitors with the virulent factor cystalysin from Treponema denticola. Bioinformation. 2023;19:94–8.

G P, Sukumaran G, E D, Ramani P. Targeting oral cancer: in silico docking studies of phytochemicals on oncogenic molecular markers. Asian Pacific J Cancer Prev. 2024;25:2069–75.

Sonsalla PK, Coleman C, Wong LY, Harris SL, Richardson JR, Gadad BS, et al. The angiotensin converting enzyme inhibitor captopril protects nigrostriatal dopamine neurons in animal models of parkinsonism. Exp Neurol. 2013;250:376–83.

Bartosz M, Kedziora J, Bartosz G. Antioxidant and prooxidant properties of captopril and enalapril. Free Radic Biol Med. 1997;23:729-35.

Benzie IFF, Tomlinson B. Antioxidant power of angiotensin‐converting enzyme inhibitors in vitro. Br J Clin Pharmacol. 1998;45:168-9.

Rees TM, Brimijoin S. The role of acetylcholinesterase in the pathogenesis of Alzheimer’s disease. Drugs Today (Barc). 2003;39:75-83.

AbdAlla S, el Hakim A, Abdelbaset A, Elfaramawy Y, Quitterer U. Inhibition of ACE Retards Tau Hyperphosphorylation and Signs of Neuronal Degeneration in Aged Rats Subjected to Chronic Mild Stress. Biomed Res Int. 2015;2015:917156. PubMed PMID: 26697495

Amin KM, Abdel Rahman DE, Abdelrasheed Allam H, El-Zoheiry HH. Design and synthesis of novel coumarin derivatives as potential acetylcholinesterase inhibitors for Alzheimer’s disease. Bioorg Chem. 2021;110:104792. PubMed PMID: 33799178

Perez-Lloret S, Otero-Losada M, Toblli JE, Capani F. Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson’s disease. Expert Opin Investig Drugs. 2017;26:1163-73.